Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 |
---|---|---|---|---|
Income Statement | ||||
Total Revenue | 1.93B | 1.90B | 1.84B | 1.72B |
Gross Profit | 523.15M | 527.98M | 439.38M | 408.19M |
EBITDA | 317.72M | 368.26M | 360.15M | 330.20M |
Net Income | 156.50M | 166.54M | 179.95M | 166.73M |
Balance Sheet | ||||
Total Assets | 2.73B | 2.52B | 2.33B | 2.30B |
Cash, Cash Equivalents and Short-Term Investments | 52.11M | 183.25M | 31.37M | 37.66M |
Total Debt | 517.97M | 1.95B | 905.00M | 1.04B |
Total Liabilities | 2.40B | 2.22B | 1.16B | 1.30B |
Stockholders Equity | 307.12M | 275.67M | 1.16B | 973.32M |
Cash Flow | ||||
Free Cash Flow | 178.93M | 210.35M | 164.98M | 228.35M |
Operating Cash Flow | 241.75M | 274.68M | 234.32M | 274.34M |
Investing Cash Flow | -343.66M | -71.27M | -75.31M | -50.93M |
Financing Cash Flow | 104.47M | -51.53M | -165.29M | -216.68M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $21.91B | 30.21 | 8.98% | 1.10% | 7.13% | 74.73% | |
65 Neutral | $2.64B | 16.69 | 20.83% | 1.22% | ― | ― | |
57 Neutral | $3.46B | ― | -31.33% | ― | -2.30% | -854.21% | |
54 Neutral | $1.93B | -6.64 | 6.82% | 2.77% | 10.18% | -64.59% | |
51 Neutral | $61.33M | ― | 84.03% | ― | -17.91% | 83.17% |
On June 26, 2025, Concentra Group Holdings Parent, Inc. announced the appointment of Vipin Gopal and Brigid Bonner to its Board of Directors, effective July 1, 2025. This strategic move is aimed at enhancing the company’s growth and shareholder value by leveraging the new directors’ expertise in data, technology, and business transformation. Vipin Gopal brings extensive experience in data and AI strategy from roles at major companies like Eli Lilly and Walgreens Boots Alliance, while Brigid Bonner offers a wealth of knowledge in strategic planning and digital transformation from her leadership roles in various sectors. The appointments are expected to strengthen Concentra’s position in the healthcare industry as it navigates technological advancements and complex market dynamics.
The most recent analyst rating on (CON) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Concentra Group Holdings Parent, Inc. stock, see the CON Stock Forecast page.
On June 1, 2025, Concentra Health Services, a subsidiary of Concentra Group Holdings Parent, Inc., completed the acquisition of Onsite Innovations for $55 million. This acquisition doubles the size of Concentra’s Onsite Health segment and aligns with its growth strategy, expanding its reach to approximately 350 onsite health clinics across over 40 states. The integration aims to enhance service offerings and maintain high-quality care, with key leaders from Onsite Innovations joining Concentra to ensure business continuity and growth.
The most recent analyst rating on (CON) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Concentra Group Holdings Parent, Inc. stock, see the CON Stock Forecast page.
On May 7, 2025, Concentra Group Holdings Parent, Inc. announced its financial results for the first quarter ended March 31, 2025, reporting a revenue increase of 7.1% to $500.8 million and an adjusted EBITDA growth of 6.8% to $102.7 million. The company declared a cash dividend of $0.0625 per share and completed the acquisition of Nova Medical Centers, enhancing its network with 67 additional centers. Concentra also signed an agreement to acquire Pivot Onsite Innovations, which will expand its onsite health clinic footprint significantly. Despite a decrease in net income due to higher interest expenses, the company raised its financial guidance for 2025, expecting revenue between $2.1 billion and $2.15 billion.
On April 21, 2025, Concentra Group Holdings Parent, Inc. announced that its subsidiary, Concentra Health Services, Inc., entered into an agreement to acquire Pivot Onsite Innovations for $55 million. This acquisition is expected to double the size of Concentra’s Onsite Health segment, expanding its reach to approximately 350 onsite health clinics in over 40 states. The transaction is anticipated to close in the second quarter of 2025, subject to customary conditions, and aims to enhance Concentra’s mission of improving workforce health by leveraging combined resources and expertise.